These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18021019)

  • 1. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
    Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
    Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
    Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
    Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
    Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
    Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
    Nasu Y; Saika T; Ebara S; Kusaka N; Kaku H; Abarzua F; Manabe D; Thompson TC; Kumon H
    Mol Ther; 2007 Apr; 15(4):834-40. PubMed ID: 17327829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
    Koeneman KS; Kao C; Ko SC; Yang L; Wada Y; Kallmes DF; Gillenwater JY; Zhau HE; Chung LW; Gardner TA
    World J Urol; 2000 Apr; 18(2):102-10. PubMed ID: 10854144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
    Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
    Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
    Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
    Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
    Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
    Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
    Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
    Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
    Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
    Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
    Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
    Chiocca EA; Aguilar LK; Bell SD; Kaur B; Hardcastle J; Cavaliere R; McGregor J; Lo S; Ray-Chaudhuri A; Chakravarti A; Grecula J; Newton H; Harris KS; Grossman RG; Trask TW; Baskin DS; Monterroso C; Manzanera AG; Aguilar-Cordova E; New PZ
    J Clin Oncol; 2011 Sep; 29(27):3611-9. PubMed ID: 21844505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.